Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ platform for recombinant viral vector manufacturing.

Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective...